Valtoco® (diazepam) – New orphan drug approval
January 13, 2020 - Neurelis announced the FDA approval of Valtoco (diazepam) nasal spray, for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (ie, seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 6 years of age and older.
Top